Loading...
NPI 1457455636 · New York, NY · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
K Freund is a ophthalmology physician provider located in New York, New York. This profile covers 13 Medicare and 9 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | K Freund |
| Address | 950 Third Avenue |
| City | New York |
| State | NY |
| ZIP | 10022 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | September 11, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.6M |
| Medicaid | $675.9K |
This provider is an ophthalmology physician with an NPI enumerated on 2006-09-11 (~20 years ago), indicating roughly two decades of Medicare/Medicaid billing history to analyze. The longevity supports stable practice operations and a billing profile concentrated in retinal and intravitreal services rather than a newly established clinic pattern.
Revenue scale is Medicare‑heavy: total Medicare revenue is $3.6M versus total Medicaid revenue of $675.9K, so Medicare is the dominant payer by reported dollars. The provider is not single‑payer — they bill both payers — but Medicare drives the majority of the reported lifetime revenue.
Intravitreal injections are the clear service-line focus across both payers. On Medicare, J0178 (aflibercept) accounts for $1.8M revenue (49.9% of this provider's total Medicare revenue) and J2777 (faricimab) accounts for $1.1M revenue (30.2% of this provider's total Medicare revenue); on Medicaid, J0178 is $478.6K (70.9% of this provider's total Medicaid revenue) and J2777 is $157.9K (23.4% of this provider's total Medicaid revenue). These figures show that high-cost injectable retinal therapeutics are the primary revenue drivers for both payers, with routine exams and imaging playing secondary roles.
Revenue concentration is very high for the top codes: the top 3 Medicare codes by revenue account for 85.3% of this provider's total Medicare revenue, and the top 3 Medicaid codes by revenue account for 97.9% of this provider's total Medicaid revenue. Those precomputed concentrations indicate the practice’s financial exposure is centered on a small set of injection and procedure codes rather than a broad mix of general ophthalmology services.
Competitive standing for the principal injection codes is mixed: J0178 ranks #298 of 3204 providers nationally (91th percentile) and is labeled as "typical, unremarkable volume," while J2777 ranks #189 of 2039 providers nationally (91th percentile) and is also described as "typical, unremarkable volume." In other words, the provider bills substantial absolute dollars for these drugs but sits within a large national cohort rather than being an extreme national outlier for those specific injections.
For office visits and diagnostic imaging the provider is an outlier in activity: 92012 (established intermediate eye exam) is $145.1K (4.1% of Medicare revenue) and ranks #93 of 17177 providers nationally (99th percentile; extreme outlier), while 92134 (retinal imaging) is $85.6K (2.4% of Medicare revenue) and ranks #691 of 26868 providers nationally (97th percentile; extreme outlier). This pattern suggests a high-volume ambulatory retinal clinic workflow with heavy utilization of intermediate exams and retinal imaging relative to peers.
Medicaid competitive posture is regionally notable for intravitreal drugs: J0178 ranks #16 of 101 providers in‑state (85th percentile) and J2777 ranks #6 of 15 providers in‑state (64th percentile), both described as typical volumes for their cohorts. While not dominant at the very top of the state leaderboards, the provider is among the more active in-state billers of these agents, especially for J0178.
Lower-revenue procedure codes and ancillary services are present but not material to total income: on Medicare, codes such as 67028 ($185.5K, 5.2% of Medicare revenue) and 92250 ($38.1K, 1.1% of Medicare revenue) appear in the top‑25 listing; 92250 ranks #166 of 25087 providers nationally (99th percentile; extreme outlier) which reinforces the provider’s emphasis on retinal documentation and imaging rather than broad-spectrum ophthalmic procedures. These lower-dollar codes support the injection-driven business model by documenting follow-up care and imaging that accompany anti-VEGF/faricimab therapy.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
13 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 2,560 | $690 | $1.8M |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 37,080 | $30 | $1.1M |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,600 | $120 | $185.5K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 1,880 | $80 | $145.1K |
| J2778 | Injection, ranibizumab, 0.1 mg | 730 | $180 | $134.3K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,450 | $40 | $85.6K |
| J3490 | Unclassified drugs | 30 | $1,770 | $56.6K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 470 | $100 | $46.9K |
| 92250 | Code 92250 describes the taking of fundus photographs, that is, photographs of the posterior segment of the inner aspect of the eye, to document alterations in the optic nerve head, retinal vessels,… | 1,150 | $30 | $38.1K |
| 92004 | The provider performs a comprehensive level ophthalmological evaluation of a new patient and initiates a diagnostic and treatment program for one or more visits. | 120 | $110 | $14.1K |
Showing 1–10 of 13
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 13 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
13 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 22 | 230 | 560 | $690 | $693K |
| J2777 | 5 | 120 | 7,740 | $30 | $364.9K |
| J2778 | 26 | 70 | 510 | $180 | $131.6K |
| 67028 | 34 | 300 | 400 | $100 | $65.9K |
| J3490 | 89 | 120 | 60 | $470 | $50.8K |
| 92014 | 470 | 2,220 | 160 | $100 | $29.3K |
| 92012 | 15 | 1,640 | 100 | $70 | $17.4K |
| 92134 | 46 | 1,580 | 90 | $30 | $11.2K |
| 92004 | 288 | 1,750 | 50 | $110 | $9.2K |
| 92083 | 1,504 | 1,630 | 70 | $50 | $6.9K |
Showing 1–10 of 13
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
9 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 940 | $510 | $478.6K |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 280 | $560 | $157.9K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,590 | $20 | $23.8K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 970 | $10 | $7.8K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 1,100 | $1 | $4.4K |
| 92250 | Code 92250 describes the taking of fundus photographs, that is, photographs of the posterior segment of the inner aspect of the eye, to document alterations in the optic nerve head, retinal vessels,… | 130 | $10 | $1.7K |
| 92201 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 210 | $1 | $410 |
| 92202 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 30 | $0 | $0 |
| 92226 | N/A | 200 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
9 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 16 | 100 | 280 | $650 | $369.9K |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 6 | 20 | 120 | $720 | $173.2K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 423 | 1,460 | 310 | $60 | $88.1K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 51 | 260 | 420 | $70 | $65.6K |
| 92250 | Code 92250 describes the taking of fundus photographs, that is, photographs of the posterior segment of the inner aspect of the eye, to document alterations in the optic nerve head, retinal vessels,… | 965 | 1,490 | 340 | $40 | $48.7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 221 | 730 | 370 | $20 | $30K |
| 92226 | N/A | 220 | 400 | 270 | $20 | $12.6K |
| 92201 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 160 | 320 | 190 | $20 | $10.7K |
| 92202 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 404 | 530 | 210 | $10 | $9.8K |
Other providers in the same ZIP code as K Freund, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Ali Aboufares | NY | Interventional Cardiology Physician | $1.3M | $2.1M |
| Wayne Fuchs | NY | Ophthalmology Physician | $1.7M | $0 |
| Brian Apatoff | NY | Neurology Physician | $708.5K | $0 |
| Ramon Valderrama | NY | Neurology Physician | $293.2K | $297.4K |
| David Bolon | NY | Cardiovascular Disease Physician | $508.4K | $350 |
| Roy Geronemus | NY | Specialist | $472.2K | $0 |
| Brian Gelbman | NY | Pulmonary Disease Physician | $426.3K | $0 |
| Alan Manevitz | NY | Psychiatry Physician | $397.9K | $0 |
| Clark Huang | NY | Specialist | $390K | $0 |
| Jacqueline Beer | NY | Specialist | $388.5K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.